

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K  
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440  
Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark  
whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F  
Form 40-F Costs Associated with Exit or Disposal  
Activities On January 28, 2025, I-MAB (the Company or I-Mab) completed a workforce reduction  
designed to right size the organization and realign the Company's clinical development support as a result of the  
Company's recently announced pipeline reprioritization (the Realignment Plan). The Realignment Plan  
reduced the Company's workforce by approximately 27%. The Company currently estimates that it will incur one-  
time cash charges associated with the Realignment Plan of approximately \$0.8 million primarily related to employee  
severance payments, benefits and related termination costs. The Realignment Plan is expected to result in annual  
operating expense savings of approximately \$3.0 million. The Company expects that the Realignment Plan will be  
substantially complete with the majority of related charges recognized in the first quarter of 2025. The estimates of the  
charges and expenditures that the Company expects to incur in connection with the Realignment Plan, and the timing  
thereof, are subject to several assumptions and the actual amounts incurred may differ materially from these estimates.  
In addition, the Company may incur other charges or cash expenditures not currently contemplated due to  
unanticipated events that may occur, including in connection with the implementation of the workforce reduction.  
Forward Looking Statements This current report on Form 6-K (the Report) contains forward-looking statements.  
These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act  
of 1995. These forward-looking statements can be identified by terminology such as will, expects, believes,  
designed to, anticipates, future, intends, plans, potential, estimates, confident, and similar terms or the negative thereof. Statements that are not historical facts,  
including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking  
statements in this Report include statements regarding: expectations related to the Realignment Plan, including  
estimated costs, charges and expenditures, impairments and the timing and financial impacts thereof; and the  
Company's expectations with respect to operational efficiencies and reduction of expenditures. Forward-looking  
statements involve inherent risks and uncertainties that may cause actual results to differ materially from those  
contained in these forward-looking statements, including: I-Mab's ability to demonstrate the safety and efficacy of  
its drug candidates; the clinical results for its drug candidates, which may or may not support further development or  
New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by  
the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to  
achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of  
intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development,  
manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional  
funding for operations and to complete the development and commercialization of its drug candidates, as well as those  
risks more fully discussed in the Risk Factors section in I-Mab's most recent annual report on Form 20-F, as  
well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with  
the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no  
obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future  
events, or otherwise, except as may be required by law. Incorporation by Reference This Report shall be deemed to be  
incorporated by reference into the registration statements on Form S-8 (File No. 333-279842, File No. 333-265684, File  
No. 333-256603 and File No. 333-239871) of the Company (including any prospectuses forming a part of such  
registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not  
superseded by documents or reports subsequently filed or furnished. SIGNATURES Pursuant to the  
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its  
behalf by the undersigned, thereunto duly authorized. I-MAB By: /s/ Joseph Skelton Name: Joseph  
Skelton Title: Chief Financial Officer Date: January 29, 2025